Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. [electronic resource]
Producer: 20200625Description: 2229-2238 p. digitalISSN:- 1433-7339
- Adult
- Aged
- Antiemetics -- therapeutic use
- Antineoplastic Agents -- adverse effects
- Aprepitant -- therapeutic use
- Brain Neoplasms -- drug therapy
- Female
- Glioma -- drug therapy
- Humans
- Male
- Middle Aged
- Nausea -- chemically induced
- Ondansetron -- therapeutic use
- Quality of Life
- Temozolomide -- adverse effects
- Vomiting -- chemically induced
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.